|

Belantamab Mafodotin-Blmf Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1/2: 2

Top Sponsors

  • Hellenic Society of Hematology2

Indications

  • Corneal Disease2
  • Haematologic Disease2
  • Gammopathy, Monoclonal2
  • Blood Protein Disorders2
  • Paraproteinemias2

Other2 trials

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Phase 1/2
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.